Hematologic Oncology

Andre Goy, MD, MS, chief, discusses the results of the multicenter FLYER trial in patients with diffuse large B-cell lymphoma.

The combination of itacitinib and corticosteroids did not induce a statistically significant improvement in overall response rate at day 28 compared with placebo plus corticosteroids in patients with treatment-naïve acute graft-versus-host disease, missing the primary endpoint of the phase III GRAVITAS-301 trial.

Seo-Hyun Kim, MD, discusses frontline treatment considerations in stage III and IV classical Hodgkin lymphoma and exciting combinations on the horizon.

Lloyd Damon, MD, discusses optimal treatment regimens in adolescent/young adult acute lymphoblastic leukemia.

Jamile M. Shammo, MD, FASCP, FACP, discusses the current treatment paradigm of myelofibrosis, criteria for ruxolitinib resistance and intolerance, and promising agents on the horizon.

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

Richard Pazdur, MD, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs section of the FDA from a poorly understood and lead-footed division into a fast-moving and patient-responsive entity.

Melissa L. Larson, MD, discusses available treatments for patients with acute myeloid leukemia, as well as others that are in the pipeline.

Jean L. Koff, MD, MS, highlights exciting advances made in follicular lymphoma and the promise of CAR T-cell therapies in other lymphoma subtypes.

William G. Blum, MD, discusses the introduction of novel agents into acute myeloid leukemia treatment and how this is impacting the role of molecular testing for patients.

An application has been submitted to the FDA for selinexor for the treatment of patients with relapsed/refractory diffuse large B-Cell lymphoma who have received at least 2 prior multiagent therapies and who are ineligible for stem cell transplantation, including CAR T-cell therapy.